|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,818,787: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 6,818,787, issued to Genentech on November 16, 2004, pertains to a monoclonal antibody therapeutic targeting the human epidermal growth factor receptor 2 (HER2/neu). This patent principally covers the antibody trastuzumab (marketed as Herceptin), its conjugates, and methods of treatment for HER2 overexpressing cancers, notably breast cancer. The patent’s broad claims set foundational IP barriers for HER2-targeted therapies. Its scope encompasses the antibody’s composition, methods of making, and therapeutic applications, significantly shaping the patent landscape related to HER2 inhibitors.
Patent Overview
| Aspect |
Details |
| Patent Number |
6,818,787 |
| Filing Date |
August 1, 2000 |
| Issue Date |
November 16, 2004 |
| Assignee |
Genentech, Inc. |
| Inventors |
Dennis J. Slamon, et al. |
| Patent Term |
20 years from the earliest filing date (approx. August 1, 2020, adjusted for patent term adjustments) |
Scope of the Patent
The patent primarily covers:
- The monoclonal antibody trastuzumab with specific amino acid sequences.
- Methods of producing trastuzumab.
- Therapeutic methods for HER2-positive cancers, especially breast carcinoma.
- Conjugates of trastuzumab with cytotoxic agents.
- Diagnostic methods for detecting HER2 overexpression.
Core Patent Claims
| Claim Type |
Details |
Significance |
| Composition of Matter |
Claims covering substantially pure monoclonal antibody with specific variable and constant regions, defining trastuzumab. |
Foundation for patent rights over the antibody itself, providing exclusive commercialization rights. |
| Methods of Production |
Claims related to hybridoma cells producing trastuzumab and recombinant DNA techniques. |
Protects methods of manufacturing, enabling biosimilar development hindrance. |
| Therapeutic Use |
Claims covering methods of treatment of HER2-overexpressing breast cancer using trastuzumab. |
Broadens scope to include therapeutic applications, influencing clinical use rights. |
| Conjugates and Compositions |
Claims on antibody-drug conjugates combining trastuzumab with cytotoxic agents. |
Extends patent protection to drug conjugate products. |
Claims Breakdown
-
Independent Claims:
- Composition of trastuzumab with specific amino acid sequence (e.g., Claim 1).
- Methods of treatment involving trastuzumab (e.g., Claim 5).
- Conjugates of trastuzumab with cytotoxic agents (e.g., Claim 13).
-
Dependent Claims:
- Variations of amino acid sequences.
- Specific conjugation chemistries.
- Specific dosages or administration regimens.
Patent Landscape and Related Patents
Key Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Relevance |
| 6,962,812 |
Humanized Anti-HER2 Antibody |
Genentech |
2002 |
Extends claims to humanized variants |
| 7,088,607 |
Trastuzumab Pharmaceutical Compositions |
Genentech |
2003 |
Covers formulation patents |
| 7,285,726 |
Antibody-Drug Conjugates for HER2 |
Genentech |
2003 |
Combines conjugates with trastuzumab |
Patent Landscape Summary
- The patent family of 6,818,787 forms the core of HER2-targeted antibody IP.
- Multiple continuation and divisional patents have expanded coverage to variants, conjugates, and formulations.
- The patent landscape is characterized by aggressive patent prosecution and broad claims, which have historically delayed biosimilar entry.
- Key jurisdictions outside the U.S. include Europe, Japan, and China, with corresponding patent families.
Patent Expiry and Lifespan
- The original patent expired in 2020; however, supplementary patents and patent term extensions can extend market exclusivity.
- Ongoing patent litigations and filings continue to influence the competitive landscape.
Claims and Monoclonal Antibody Coverage
Legal Scope of Trastuzumab Patent
- The claims cover the antibody's amino acid sequence, methods of producing, and mechanisms of therapeutic action.
- Post-grant, the patent acts as an obstacle for biosimilar development unless challenged or licensed.
Comparison with Biosimilar Patents
| Aspect |
Herceptin (trastuzumab) |
Biosimilar Patents (e.g., Z designs) |
| Patent Protections |
Broad composition and method claims |
Often narrower, focusing on manufacturing processes or specific formulations |
| Patent Challenges |
Limited in certain jurisdictions |
Increasing challenges via patent cliffs and regulatory pathways |
Regulatory and Policy Context
- FDA approval granted in 1998, with trastuzumab becoming a standard of care.
- Patent protections restrict biosimilar entry until patent expiry or settlement.
- The Biologics Price Competition and Innovation Act (BPCIA) provides abbreviated pathways for biosimilars, but patent barriers remain significant.
Comparison with Similar Therapeutics
| Drug |
Target |
Patent Status |
Notable Claims |
Market Impact |
| Rituximab |
CD20 |
Similar core patent landscape |
Composition & use |
Market pioneer in monoclonal antibodies |
| Bevacizumab |
VEGF |
Extended exclusivity |
Composition & methods |
Broad anti-angiogenic applications |
FAQs
1. How does U.S. Patent 6,818,787 influence biosimilar development for trastuzumab?
This patent provides foundational IP, particularly the claims on the antibody's composition and production methods. Its scope acts as a barrier to biosimilar entry until patent expiration or legal challenges are resolved.
2. Are there any known patent litigations related to this patent?
Yes. Multiple litigations and patent disputes, especially around biosimilar applications (e.g., those initiated by Celltrion and Pfizer), have contested the validity and scope of the original patent.
3. What are the key differences between the patent claims and later trastuzumab variants?
Later variants, like trastuzumab-Hy (Herceptin Hylecta), involve modifications that may or may not fall within the original patent scope, often leading to new patent filings with narrower claims.
4. How does the patent landscape impact global HER2-targeted therapies?
While U.S. patents provide strong protection domestically, similar patent families and legal battles govern other jurisdictions, influencing the global market dynamics.
5. What strategies do generic manufacturers use to design biosimilars around such patents?
Strategies include developing structurally similar but non-infringing variants, focusing on manufacturing process innovations, or entering legal challenges to patent validity.
Key Takeaways
- U.S. Patent 6,818,787 is a foundational patent providing broad claims over trastuzumab, significantly influencing the HER2-targeted therapeutic market.
- Its scope extends across composition, production, and therapeutic methods, creating substantial IP barriers for biosimilar development.
- The patent landscape involves an intricate network of related patents, continuation applications, and jurisdiction-specific filings.
- Patent expiry in 2020 opened pathways for biosimilar entry; however, patent challenges and supplementary protections continue to shape competition.
- Stakeholders should remain vigilant to patent litigations, licensing opportunities, and regulatory pathways impacting HER2-targeted antibody development.
References
[1] U.S. Patent and Trademark Office. Patent No. 6,818,787. Issued Nov 16, 2004.
[2] Genentech. Patent family and product information. (2023).
[3] Food and Drug Administration. Herceptin (trastuzumab) approval details. (1998).
[4] Lee, M. et al., "HER2-targeted therapies and patent landscape," Nature Reviews Drug Discovery, 2021.
[5] FDA.gov, "Biologics Price Competition and Innovation Act (BPCIA)," 2010.
This analysis provides a comprehensive understanding necessary for strategic patent management, licensing negotiations, and competitive forecasting regarding HER2-targeted monoclonal antibodies.
More… ↓
⤷ Start Trial
|
